Moneycontrol PRO
Register now: Moneycontrol & Property Share present a webinar on Wealth Generation Through Commercial Real Estate on Thursday, 30th March 2023 | 5 pm onwards.

Buy Eris Lifesciences; target of Rs 780: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 780 in its research report dated March 17, 2023.

March 17, 2023 / 01:27 PM IST
  • bselive
  • nselive
Todays L/H

Prabhudas Lilladher's research report on Eris Lifesciences

Eris Lifesciences (ERIS) acquisition of nine derma brands from Dr Reddy along with recent acquisition of brands from Glenmark will provide them comprehensive offerings in dermatology. In the near term, this acquisition will increase ERIS net debt and we see this acquisition as EPS dilutive. We downgrade our FY24E and FY25E EPS estimates by 9% and 3% each, given higher depreciation and interest cost. The company has multiple growth levers such as broad based offerings in derma segment, opportunities in cardio metabolic market with patent expirations and benefits of operating leverage, as revenue scales up from these acquisitions which is currently operating at sub optimal profitability.


We maintain our ‘BUY’ rating with revised TP of Rs780 (Rs850 earlier), valuing 14x EV/EBITDA on FY25E.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Eris Lifesciences - 17 -03 - 2023 - prabhu

Broker Research
first published: Mar 17, 2023 01:27 pm